ipamorelin
Ipamorelin is a synthetic pentapeptide ghrelin-receptor agonist. People seek it for sleep, recovery, and body composition, but direct human studies measured an acute intravenous GH pulse and a negative ileus outcome.
tier C · growth hormone · 114 patients in the negative ileus trial
verdict
Ipamorelin released GH after intravenous infusion, but it has no controlled human sleep, recovery, muscle, or body-composition outcome trial. Its selectivity case comes mainly from swine and rodent work.
the core tension
The compound has direct human IV pharmacology, but its popular chronic subcutaneous outcomes remain untested and its selectivity case is predominantly preclinical.
what it is
Ipamorelin, also called NNC 26-0161, is a synthetic pentapeptide agonist of the ghrelin receptor GHS-R1a.
what it does
In healthy volunteers, five 15-minute intravenous infusions produced dose-related growth-hormone release. The 0.67-hour GH peak is a pharmacodynamic response, not a drug-concentration Tmax.
origin
The selectivity profile was established mainly in swine and later rodent studies. Those experiments do not establish a clean comparative endocrine profile in people.
does it work
The 114-patient postoperative-ileus trial found no significant difference from placebo on its primary endpoint. No controlled human sleep, recovery, muscle, or body-composition outcome trial is in the reviewed exact-compound record.
key facts
- molecular formula: C38H49N9O5
- molecular weight: 711.85 Da
- amino acids: 5
- half-life: about 2 hours after intravenous infusion
- type: synthetic pentapeptide GHS-R1a agonist
- 2 h human IV terminal half-life
- 114 patients in the negative trial
- 0 controlled human sleep trials
frequently asked questions
What is ipamorelin?
It is a synthetic pentapeptide ghrelin-receptor agonist studied as NNC 26-0161.
Does ipamorelin improve sleep or body composition?
No controlled exact-compound human trial has established those outcomes. Six internal Community Trials reports are anecdotal and remain separate from clinical evidence.
What happened in the human clinical trial?
A 114-patient intravenous postoperative-ileus trial did not significantly improve its primary endpoint.
Is ipamorelin FDA approved?
No. FDA also identifies immunogenicity, impurity, and route-specific safety concerns for compounded use.
related peptides
- sermorelin: GHRH-receptor agonist with historical pediatric products
- sermorelin + GHRP-2: different ghrelin-receptor component
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.